Interventional Oncology Ablation Market, By Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation ), By Indication (Liver Cancer, Kidney Cancer, Lung Cancer, Others), By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Published In : Oct 2023

Code : CMI4445

Pages :389

Formats :

Excel and PDF

Industry : Medical Devices

Market News

Global Interventional Oncology Ablation Market: Key Developments

On April 4, 2023, Ethicon, a part of Johnson & Johnson MedTech Company, announced the first patient treated in the North America with robot-assisted transbronchial microwave ablation as part of the global Ethicon POWER Study. The study involves leading global thoracic oncology centers and is intended to enroll patients with oligometastatic (OML) tumors in the lung.
In December, 2022, Novian Health received Frost & Sullivan’s 2022 European New Product Innovation Award in the breast tumor ablation industry for its Novilase Breast Therapy system. Novilase is a laser ablation to destroy tumors as an alternative to surgery.
In July 2022, Medtronic Plc medical device company introduced first-in-world lung ablation procedure with the ILLUMISITE fluoroscopic navigation platform. The ILLUMISITE platform navigates accurately to the most distant areas of the lung and can sample multi-directionally for a thorough biopsy.
In September 2021, Boston Scientific Corporation a biotechnology company acquired Devoro Medical a medical device company to expand Boston Scientific's ablation portfolio with Devoro's WOLF TheraSphere microwave ablation system. It enhanced Boston Scientific's leadership in interventional oncology and ability to provide minimally invasive cancer care.
In August 2021, AngioDynamics a medical technology company received U.S. Food and Drug Administration approval for its Exiru radiofrequency ablation system for treating lung tumors. This system uses advanced technology to ablate soft tissue with precision and control. The approval allowed AngioDynamics to enter the growing lung ablation market in the U.S.